Article information
Abstract
Screening plays an important role in women with a high risk of breast cancer. Given this population's high incidence of breast cancer and younger age of onset compared to the general population, it is recommended that screening starts earlier. There is ample evidence that magnetic resonance imaging (MRI) is the most sensitive diagnostic tool, and American and the European guidelines both recommend annual MRI screening (with supplementary annual mammography) as the optimum screening modality. Nevertheless, the current guidelines do not totally agree about the recommendations for MRI screening in some subgroups of patients. The first part of this article on screening in women with increased risk of breast cancer reviews the literature to explain and evaluate the advantages of MRI screening compared to screening with mammography alone: increased detection of smaller cancers with less associated lymph node involvement and a reduction in the rate of interval cancers, which can have an impact on survival and mortality (with comparable effects to other preventative measures). At the same time, however, we would like to reflect on the drawbacks of MRI screening that affect its applicability.
Keywords:
Cancer screening
Magnetic resonance imaging
Mammography
Breast tumours
Risk factors
Genetic predisposition to disease
Sensitivity and specificity
Resumen
En mujeres con alto riesgo de padecer cáncer de mama, la detección precoz tiene un importante papel. Debido a la alta incidencia de cáncer mamario y a edades más tempranas que en la población general, se recomienda que el cribado comience en edad más joven, y existe amplia evidencia de que la resonancia magnética es la herramienta diagnóstica más sensible: las principales guías americanas y europeas coinciden en la recomendación de realizar resonancia magnética anual (con mamografía anual suplementaria) como modalidad óptima de cribado. No obstante, no hay un total consenso actual entre las guías sobre algunos subgrupos de pacientes a incluir en la recomendación de cribado con resonancia magnética.
El objetivo de esta primera parte de nuestro trabajo es, mediante una revisión de la bibliografía, explicar y valorar las ventajas que este tipo de cribado con resonancia magnética proporciona respecto al cribado solo con mamografía, como son: mayor detección de cánceres de menor tamaño y con menor afectación ganglionar asociada y una reducción de los cánceres de intervalo, lo que puede tener repercusión en supervivencia y mortalidad, con efectos comparables a otras medidas de prevención. Pero, a su vez, también queremos reflejar los inconvenientes que el cribado con resonancia magnética conlleva, y que dificultan su aplicabilidad.
Palabras clave:
Detección precoz de cáncer
Resonancia magnética
Mamografía
Neoplasias mamarias
Factores de riesgo
Predisposición genética a la enfermedad
Sensibilidad y especificidad
Article
These are the options to access the full texts of the publication Radiología (English Edition)
Subscriber
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
References
[1]
H.D. Nelson, K. Tyne, A. Naik, C. Bougatsos, B.K. Chan, L. Humphrey.
Screening for breast cancer: an update for the U.S Preventive Services Task Force.
Ann Intern Med, 151 (2009), pp. 727-737
[2]
M.G. Marmot, D.G. Altman, D.A. Cameron, J.A. Dewar, S.G. Thompson, M. Wilcox.
The benefits and harms of breast cancer screening: an independent review.
Br J Cancer, 108 (2013), pp. 2205-2240
[3]
R.M. Mann, C. Balleyguier, P.A. Baltzer, U. Bick, C. Colin, E. Cornford, et al.
Breast MRI: EUSOBI recommendations for women's information.
Eur Radiol, 25 (2015), pp. 3669-3678
[4]
F. Sardanelli, C. Boetes, B. Borisch, T. Decker, M. Federico, F.J. Gilbert, Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group, et al.
Eur J Cancer, 46 (2010), pp. 1296-1316
[5]
R.A. Smith, K.S. Andrews, D. Brooks, S.A. Fedewa, D. Manassaram-Baptiste, D. Saslow, et al.
Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening.
CA Cancer J Clin, 68 (2018), pp. 297-316
[6]
C.H. Lee, D.D. Dershaw, D. Kopans, P. Evans, B. Monsees, D. Monticciolo, et al.
Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer.
J Am Coll Radiol, 7 (2010), pp. 18-27
[7]
BOADICEA web application. Available from: https://ccge.medschl.cam.ac.uk/boadicea/boadicea-web-application/ [accessed 20.03.19].
[8]
D.L. Monticciolo, M.S. Newell, L. Moy, B. Niell, B. Monsees, E.A. Sickles.
Breast cancer screening in women at higher-than-average risk: recommendations from the ACR.
J Am Coll Radiol, 15 (2018), pp. 408-414
[9]
E.C. Group, S. Darby, P. McGale, C. Correa, C. Taylor, R. Arriagada, et al.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Lancet, 378 (2011), pp. 1707-1716
[10]
R.S. Punglia, M.J. Hassett.
Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors.
J Clin Oncol, 28 (2010), pp. 4108-4110
[11]
N. Houssami, L.A. Abraham, D.L. Miglioretti, E.A. Sickles, K. Kerlikowske, D.S. Buist, et al.
Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer.
JAMA, 305 (2011), pp. 790-799
[12]
N. Houssami, N. Cho.
Screening women with a personal history of breast cancer: overview of the evidence on breast imaging surveillance.
Ultrasonography, 37 (2018), pp. 277-287
[13]
S. Brennan, L. Liberman, D.D. Dershaw, E. Morris.
Breast MRI screening of women with a personal history of breast cancer.
Am J Roentgenol, 195 (2010), pp. 510-516
[14]
H.M. Gweon, N. Cho, W. Han, A. Yi, H.-G. Moon, D.-Y. Noh, et al.
Breast MR imaging screening in women with a history of breast conservation therapy.
Radiology, 272 (2014), pp. 366-373
[15]
C.S. Giess, P.S. Poole, S.A. Chikarmane, D.A. Sippo, R.L. Birdwell.
Screening breast MRI in patients previously treated for breast cancer: diagnostic yield for cancer and abnormal interpretation rate.
Acad Radiol, 22 (2015), pp. 1331-1337
[16]
C.D. Lehman, J.M. Lee, W.B. DeMartini, D.S. Hippe, M.H. Rendi, G. Kalish, et al.
Screening MRI in women with a personal history of breast cancer.
J Natl Cancer Inst, 108 (2016),
[17]
R.M. Strigel, J. Rollenhagen, E.S. Burnside, M. Elezaby, A.M. Fowler, F. Kelcz, et al.
Screening breast MRI outcomes in routine clinical practice: comparison to BI-RADS benchmarks.
Acad Radiol, 24 (2017), pp. 411-417
[18]
F. Cardoso, S. Kyriakides, S. Ohno, F. Penault-Llorca, P. Poortmans, I.T. Rubio, et al.
Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
Ann Oncol, 30 (2019), pp. 1674
[19]
D.L. Lam, N. Houssami, J.M. Lee.
Imaging surveillance after primary breast cancer treatment.
Am J Roentgenol, 208 (2017), pp. 676-686
[20]
S.E. Song, N. Cho, J.M. Chang, A.J. Chu, A. Yi, W.K. Moon.
Diagnostic performances of supplemental breast ultrasound screening in women with personal history of breast cancer.
Acta Radiol, 59 (2018), pp. 533-539
[21]
W.A. Berg, Z. Zhang, D. Lehrer, R.A. Jong, E.D. Pisano, R.G. Barr, et al.
Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.
JAMA, 307 (2012), pp. 1394-1404
[22]
A.S. Tagliafico, G. Mariscotti, F. Valdora, M. Durando, J. Nori, D. La Forgia, et al.
A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2).
Eur J Cancer, 104 (2018), pp. 39-46
[23]
F.J. Gilbert, A. Selamoglu.
Personalised screening: is this the way forward?.
Clin Radiol, 73 (2018), pp. 327-333
[24]
M.H. Helal, S.M. Mansour, H.A. Ahmed, A.F. Abdel Ghany, O.F. Kamel, N.G. Elkholy.
The role of contrast-enhanced spectral mammography in the evaluation of the postoperative breast cancer.
Clin Radiol, 74 (2019), pp. 771-781
[25]
M. Algara López, F. Vicente García, E. Adrover Cebrian, M. Prats de Puig, M. González Bejar, M.D. Sabadell Mercadal.
Consenso de seguimiento en pacientes con cáncer de mama de la Sociedad Española de Senología y Patología mamaria.
Rev Senol Patol Mamar, 28 (2015), pp. 24-33
[26]
F. Ayala de la Peña, R. Andrés, J.A. Garcia-Sáenz, L. Manso, M. Margelí, E. Dalmau, et al.
SEOM clinical guidelines in early stage breast cancer (2018).
Clin Transl Oncol, 21 (2019), pp. 18-30
[27]
M. Nadler, H. Al-Attar, E. Warner, A.L. Martel, S. Balasingham, L. Zhang, et al.
MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion.
Breast, 34 (2017), pp. 77-82
[28]
L.C. Friedlander, S.O. Roth, S.C. Gavenonis.
Results of MR imaging screening for breast cancer in high-risk patients with lobular carcinoma in situ.
Radiology, 261 (2011), pp. 421-427
[29]
J.S. Sung, S.F. Malak, P. Bajaj, R. Alis, D.D. Dershaw, E.A. Morris.
Screening breast MR imaging in women with a history of lobular carcinoma in situ.
Radiology, 261 (2011), pp. 414-420
[30]
E.R. Port, A. Park, P.I. Borgen, E. Morris, L.L. Montgomery.
Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia.
Ann Surg Oncol, 14 (2007), pp. 1051-1057
[31]
M. Kriege, C.T. Brekelmans, C. Boetes, P.E. Besnard, H.M. Zonderland, I.M. Obdeijn, et al.
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.
N Eng J Med, 351 (2004), pp. 427-437
[32]
E. Warner, D.B. Plewes, K.A. Hill, P.A. Causer, J.T. Zubovits, R.A. Jong, et al.
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
JAMA, 292 (2004), pp. 1317-1325
[33]
M.O. Leach, C.R. Boggis, A.K. Dixon, D.F. Easton, R.A. Eeles, D.G. Evans, et al.
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).
Lancet, 365 (2005), pp. 1769-1778
[34]
F. Sardanelli, F. Podo, G. D’Agnolo, A. Verdecchia, M. Santaquilani, R. Musumeci, et al.
Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results.
Radiology, 242 (2007), pp. 698-715
[35]
C.K. Kuhl, S. Schrading, C.C. Leutner, N. Morakkabati-Spitz, E. Wardelmann, R. Fimmers, et al.
Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer.
J Clin Oncol, 23 (2005), pp. 8469-8476
[36]
C.D. Lehman, J.D. Blume, P. Weatherall, D. Thickman, N. Hylton, E. Warner, et al.
Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.
Cancer, 103 (2005), pp. 1898-1905
[37]
A.I. Hagen, K.A. Kvistad, L. Maehle, M.M. Holmen, H. Aase, B. Styr, et al.
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series.
Breast, 16 (2007), pp. 367-374
[38]
C.C. Riedl, L. Ponhold, D. Flöry, M. Weber, R. Kroiss, T. Wagner, et al.
Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer.
Clin Cancer Res, 13 (2007), pp. 6144-6152
[39]
E. Warner, H. Messersmith, P. Causer, A. Eisen, R. Shumak, D. Plewes.
Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer.
Ann Intern Med, 148 (2008), pp. 671-679
[40]
S.P. Weinstein, A.R. Localio, E.F. Conant, M. Rosen, K.M. Thomas, M.D. Schnall.
Multimodality screening of high-risk women: a prospective cohort study.
J Clin Oncol, 27 (2009), pp. 6124-6128
[41]
C. Kuhl, S. Weigel, S. Schrading, B. Arand, H. Bieling, R. König, et al.
Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.
J Clin Oncol, 28 (2010), pp. 1450-1457
[42]
F. Sardanelli, F. Podo, F. Santoro, S. Manoukian, S. Bergonzi, G. Trecate, et al.
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results.
Invest Radiol, 46 (2011), pp. 94-105
[43]
C.C. Riedl, N. Luft, C. Bernhart, M. Weber, M. Bernathova, M.K. Tea, et al.
Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
J Clin Oncol, 33 (2015), pp. 1128-1135
[44]
H.J. Pederson, C. O’Rourke, J. Lyons, R.J. Patrick, J.P. Crowe Jr., S.R. Grobmyer.
Time-related changes in yield and harms of screening breast magnetic resonance imaging.
Clin Breast Cancer, 15 (2015), pp. 348-352
[45]
S. Vreemann, A. Gubern-Mérida, M.S. Schlooz-Vries, P. Bult, C.H. van Gils, N. Hoogerbrugge, et al.
Influence of risk category and screening round on the performance of an MR imaging and mammography screening program in carriers of the BRCA mutation and other women at increased risk.
Radiology, 286 (2018), pp. 443-451
[46]
E. Warner, K. Hill, P. Causer, D. Plewes, R. Jong, M. Yaffe, et al.
Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.
J Clin Oncol, 29 (2011), pp. 1664-1669
[47]
D.G. Evans, N. Kesavan, Y. Lim, S. Gadde, E. Hurley, N.J. Massat, et al.
MRI breast screening in high-risk women: cancer detection and survival analysis.
Breast Cancer Res Treat, 145 (2014), pp. 663-672
[48]
A.J. Rijnsburger, I.M. Obdeijn, R. Kaas, M.M. Tilanus-Linthorst, C. Boetes, C.E. Loo, et al.
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
J Clin Oncol, 28 (2010), pp. 5265-5273
[49]
K. Passaperuma, E. Warner, P.A. Causer, K.A. Hill, S. Messner, J.W. Wong, et al.
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
Br J Cancer, 107 (2012), pp. 24-30
[50]
F. Podo, F. Santoro, G. Di Leo, S. Manoukian, C. de Giacomi, S. Corcione, et al.
Triple-negative versus non-triple-negative breast cancers in high-risk women: phenotype features and survival from the HIBCRIT-1 MRI-including screening study.
Clin Cancer Res, 22 (2016), pp. 895-904
[51]
P. Møller, A. Stormorken, C. Jonsrud, M.M. Holmen, A.I. Hagen, N. Clark, et al.
Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
Breast Cancer Res Treat, 139 (2013), pp. 155-161
[52]
D.G. Evans, E.F. Harkness, A. Howell, M. Wilson, E. Hurley, M.M. Holmen, et al.
Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.
Hered Cancer Clin Pract, 14 (2016), pp. 8
[53]
S. Saadatmand, I.M. Obdeijn, E.J. Rutgers, J.C. Oosterwijk, R.A. Tollenaar, G.H. Woldringh, et al.
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
In J Cancer, 137 (2015), pp. 1729-1738
[54]
V.R. Grann, P.R. Patel, J.S. Jacobson, E. Warner, D.F. Heitjan, M. Ashby-Thompson, et al.
Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.
Breast Cancer Res Treat, 125 (2011), pp. 837-847
[55]
A.W. Kurian, B.M. Sigal, S.K. Plevritis.
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers.
J Clin Oncol, 28 (2010), pp. 222-231
[56]
B.A. Heemskerk-Gerritsen, M.B. Menke-Pluijmers, A. Jager, M.M. Tilanus-Linthorst, L.B. Koppert, I.M. Obdeijn, et al.
Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.
Ann Oncol, 24 (2013), pp. 2029-2035
[57]
X. Li, R. You, X. Wang, C. Liu, Z. Xu, J. Zhou, et al.
Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review.
Clin Cancer Res, 22 (2016), pp. 3971-3981
[58]
C. Taneja, J. Edelsberg, D. Weycker, A. Guo, G. Oster, J. Weinreb.
Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women.
J Am Coll Radiol, 6 (2009), pp. 171-179
[59]
J.M. Lee, P.M. McMahon, C.Y. Kong, D.B. Kopans, P.D. Ryan, E.M. Ozanne, et al.
Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.
Radiology, 254 (2010), pp. 793-800
[60]
S. Feig.
Comparison of costs and benefits of breast cancer screening with mammography, ultrasonography, and MRI.
Obstet Gynecol Clin N Am, 38 (2011), pp. 179-196
[61]
R. Pataky, L. Armstrong, S. Chia, A.J. Coldman, C. Kim-Sing, B. McGillivray, et al.
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
BMC Cancer, 13 (2013), pp. 339
[62]
C.H. Ahern, Y.C. Shih, W. Dong, G. Parmigiani, Y. Shen.
Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.
Br J Cancer, 111 (2014), pp. 1542-1551
[63]
D. Leithner, L. Moy, E.A. Morris, M.A. Marino, T.H. Helbich, K. Pinker.
Abbreviated MRI of the breast: does it provide value?.
J Magn Reson Imaging, 49 (2019), pp. e85-e100
[64]
C.K. Kuhl, S. Schrading, K. Strobel, H.H. Schild, R.D. Hilgers, H.B. Bieling.
Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection – a novel approach to breast cancer screening with MRI.
J Clin Oncol, 32 (2014), pp. 2304-2310
[65]
V.L. Mango, E.A. Morris, D. David Dershaw, A. Abramson, C. Fry, C.S. Moskowitz, et al.
Abbreviated protocol for breast MRI: are multiple sequences needed for cancer detection?.
Eur J Radiol, 84 (2015), pp. 65-70
[66]
B. Panigrahi, L. Mullen, E. Falomo, B. Panigrahi, S. Harvey.
An abbreviated protocol for high-risk screening breast magnetic resonance imaging: impact on performance metrics and BI-RADS assessment.
Acad Radiol, 24 (2017), pp. 1132-1138
[67]
L.J. Grimm, M.S. Soo, S. Yoon, C. Kim, S.V. Ghate, K.S. Johnson.
Abbreviated screening protocol for breast MRI: a feasibility study.
Acad Radiol, 22 (2015), pp. 1157-1162
[68]
L. Heacock, A.N. Melsaether, S.L. Heller, Y. Gao, K.M. Pysarenko, J.S. Babb, et al.
Evaluation of a known breast cancer using an abbreviated breast MRI protocol: correlation of imaging characteristics and pathology with lesion detection and conspicuity.
Eur J Radiol, 85 (2016), pp. 815-823
[69]
M. Moschetta, M. Telegrafo, L. Rella, A.A. Stabile Ianora, G. Angelelli.
Abbreviated combined MR protocol: a new faster strategy for characterizing breast lesions.
Clin Breast Cancer, 16 (2016), pp. 207-211
[70]
D.A. Strahle, D.R. Pathak, A. Sierra, S. Saha, C. Strahle, K. Devisetty.
Systematic development of an abbreviated protocol for screening breast magnetic resonance imaging.
Breast Cancer Res Treat, 162 (2017), pp. 283-295
[71]
B. Platel, R. Mus, T. Welte, N. Karssemeijer, R. Mann.
Automated characterization of breast lesions imaged with an ultrafast DCE-MR protocol.
IEEE Trans Med Imaging, 33 (2014), pp. 225-232
[72]
R.M. Mann, R.D. Mus, J. van Zelst, C. Geppert, N. Karssemeijer, B. Platel.
A novel approach to contrast-enhanced breast magnetic resonance imaging for screening: high-resolution ultrafast dynamic imaging.
Invest Radiol, 49 (2014), pp. 579-585
[73]
F.D. Pineda, M. Medved, S. Wang, X. Fan, D.V. Schacht, C. Sennett, et al.
Ultrafast bilateral DCE-MRI of the breast with conventional fourier sampling: preliminary evaluation of semi-quantitative analysis.
Acad Radiol, 23 (2016), pp. 1137-1144
[74]
H. Abe, N. Mori, K. Tsuchiya, D.V. Schacht, F.D. Pineda, Y. Jiang, et al.
Kinetic analysis of benign and malignant breast lesions with ultrafast dynamic contrast-enhanced MRI: comparison with standard kinetic assessment.
Am J Roentgenol, 207 (2016), pp. 1159-1166
[75]
G. Oldrini, B. Fedida, J. Poujol, J. Felblinger, I. Trop, P. Henrot, et al.
Abbreviated breast magnetic resonance protocol: value of high-resolution temporal dynamic sequence to improve lesion characterization.
Eur J Radiol, 95 (2017), pp. 177-185
[76]
C. Spick, P.A. Baltzer.
Diagnostic utility of second-look US for breast lesions identified at MR imaging: systematic review and meta-analysis.
Radiology, 273 (2014), pp. 401-409
[77]
P. Peter, R. Dhillon, S. Bose, A. Bourke.
MRI screening-detected breast lesions in high-risk young women: the value of targeted second-look ultrasound and imaging-guided biopsy.
Clin Radiol, 71 (2016), pp. 1037-1043
[78]
S.H. Lee, S.M. Kim, M. Jang, B.L. Yun, E. Kang, S.W. Kim, et al.
Role of second-look ultrasound examinations for MR-detected lesions in patients with breast cancer.
Ultraschall Med, 36 (2015), pp. 140-148
[79]
Y. Gao, N.R. Bagadiya, M.L. Jardon, S.L. Heller, A.N. Melsaether, H.B. Toth, et al.
Outcomes of preoperative MRI-guided needle localization of nonpalpable mammographically occult breast lesions.
Am J Roentgenol, 207 (2016), pp. 676-684
[80]
G.A.C. Carneiro, F.P.A. Pereira, F.P.P.L. Lopes, M.J.G. Calas.
Magnetic resonance imaging-guided vacuum-assisted breast biopsy: experience and preliminary results of 205 procedures.
Radiol Bras, 51 (2018), pp. 351-357
[81]
T. Kanda, K. Ishii, H. Kawaguchi, K. Kitajima, D. Takenaka.
High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.
Radiology, 270 (2014), pp. 834-841
[82]
E.A. Morris.
Rethinking breast cancer screening: ultra FAST breast magnetic resonance imaging.
J Clin Oncol, 32 (2014), pp. 2281-2283
[83]
C.K. Kuhl, A. Keulers, K. Strobel, H. Schneider, N. Gaisa, S. Schrading.
Not all false positive diagnoses are equal: on the prognostic implications of false-positive diagnoses made in breast MRI versus in mammography/digital tomosynthesis screening.
Breast Cancer Res, 20 (2018), pp. 13
[84]
A.J. Maxwell, Y.Y. Lim, E. Hurley, D.G. Evans, A. Howell, S. Gadde.
False-negative MRI breast screening in high-risk women.
Clin Radiol, 72 (2017), pp. 207-216
[85]
A. Gubern-Mérida, S. Vreemann, R. Martí, J. Melendez, S. Lardenoije, R.M. Mann, et al.
Automated detection of breast cancer in false-negative screening MRI studies from women at increased risk.
Eur J Radiol, 85 (2016), pp. 472-479
[86]
K. Yamaguchi, D. Schacht, G.M. Newstead, A.R. Bradbury, M.S. Verp, O.I. Olopade, et al.
Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases.
Am J Roentgenol, 201 (2013), pp. 1155-1163
[87]
E.B. Pages, I. Millet, D. Hoa, F.C. Doyon, P. Taourel.
Undiagnosed breast cancer at MR imaging: analysis of causes.
Radiology, 264 (2012), pp. 40-50
[88]
I.M. Obdeijn, C.E. Loo, A.J. Rijnsburger, M.N. Wasser, E. Bergers, T. Kok, et al.
Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition.
Breast Cancer Res Treat, 119 (2010), pp. 399-407
[89]
F.J. Gilbert, R.M. Warren, G. Kwan-Lim, D.J. Thompson, R.A. Eeles, D.G. Evans, et al.
Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
Radiology, 252 (2009), pp. 358-368
[90]
P. Clauser, E. Cassano, A. De Nicolò, A. Rotili, B. Bonanni, M. Bazzocchi, et al.
Foci on breast magnetic resonance imaging in high-risk women: cancer or not?.
Radiol Med, 121 (2016), pp. 611-617
[91]
S.B. Brennan, J. Sung, C. Lee, D.D. Dershaw, E. Morris.
Lessons learned from MR-guided breast-biopsy.
Eur J Radiol, 81 (2012), pp. S10
[92]
V.A. Arasu, D.L. Miglioretti, B.L. Sprague, N.H. Alsheik, D.S.M. Buist, L.M. Henderson, et al.
Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk.
J Clin Oncol, 37 (2019), pp. 954-963
[93]
L.J. Grimm, A. Saha, S.V. Ghate, C. Kim, M.S. Soo, S.C. Yoon, et al.
Relationship between background parenchymal enhancement on high-risk screening MRI and future breast cancer risk.
Acad Radiol, 26 (2019), pp. 69-75
[94]
M. Telegrafo, L. Rella, A.A. Stabile Ianora, G. Angelelli, M. Moschetta.
Effect of background parenchymal enhancement on breast cancer detection with magnetic resonance imaging.
Diagn Interv Imaging, 97 (2016), pp. 315-320
[95]
T. Uematsu, M. Kasami, J. Watanabe.
Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer?.
Eur Radiol, 21 (2011), pp. 2261-2267
[96]
L. Liberman, E.A. Morris, M.J. Lee, J.B. Kaplan, L.R. LaTrenta, J.H. Menell, et al.
Breast lesions detected on MR imaging: features and positive predictive value.
Am J Roentgenol, 179 (2002), pp. 171-178
[97]
M.D. Schnall, J. Blume, D.A. Bluemke, G.A. DeAngelis, N. DeBruhl, S. Harms, et al.
Diagnostic architectural and dynamic features at breast MR imaging: multicenter study.
Radiology, 238 (2006), pp. 42-53
[98]
M.A. Marino, C.C. Riedl, M. Bernathova, C. Bernhart, P.A.T. Baltzer, T.H. Helbich, et al.
Imaging phenotypes in women at high risk for breast cancer on mammography, ultrasound, and magnetic resonance imaging using the fifth edition of the breast imaging reporting and data system.
Eur J Radiol, 106 (2018), pp. 150-159
[99]
S.E. Song, N. Cho, W. Han.
Post-clip placement MRI following second-look US-guided core biopsy for suspicious lesions identified on breast MRI.
Eur Radiol, 27 (2017), pp. 5196-5203
[100]
C.E. Edmonds, L.R. Lamb, S.F. Mercaldo, D.A. Sippo, K.S. Burk, C.D. Lehman.
Frequency and cancer yield of BI-RADS category 3 lesions detected at high-risk screening breast MRI.
Am J Roentgenol, 4 (2019), pp. 1-9
